Strong humoral response after Covid-19 vaccination correlates with the common HLA allele A*03:01 and protection from breakthrough infection.
Journal
HLA
ISSN: 2059-2310
Titre abrégé: HLA
Pays: England
ID NLM: 101675570
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
revised:
14
02
2024
received:
27
12
2023
accepted:
16
02
2024
medline:
4
3
2024
pubmed:
4
3
2024
entrez:
4
3
2024
Statut:
ppublish
Résumé
Few data exist on the role of genetic factors involving the HLA system on response to Covid-19 vaccines. Moving from suggestions of a previous study investigating the association of some HLA alleles with humoral response to BNT162b2, we here compared the HLA allele frequencies among weak (n = 111) and strong (n = 123) responders, defined as those healthcare workers with the lowest and the highest anti-Spike antibody levels after vaccination. Individuals with clinical history of Covid-19 or positive anti-nucleocapside antibodies were excluded. We found the common HLA-A*03:01 allele as an independent predictor of strong humoral response (OR = 12.46, 95% CI: 4.41-35.21, p < 0.0001), together with younger age of vaccines (p = 0.004). Correlation between antibody levels and protection from breakthrough infection has been observed, with a 2-year cumulative incidence of 42% and 63% among strong and weak responders, respectively (p = 0.03). Due to the high frequency of HLA-A*03:01 and the need for seasonal vaccinations against SARS-CoV-2 mutants, our findings provide useful information about the inter-individual differences observed in humoral response after Covid-19 vaccine and might support further studies on the next seasonal vaccines.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15421Informations de copyright
© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Collatuzzo G, Visci G, Violante FS, et al. Determinants of anti-S immune response at 6 months after COVID-19 vaccination in a multicentric European cohort of healthcare workers - ORCHESTRA project. Front Immunol. 2022 Sep;29(13):986085. doi:10.3389/fimmu.2022.986085
Oliveira-Silva J, Reis T, Lopes C, et al. Humoral response to the SARS-CoV-2 BNT162b2 mRNA vaccine: real-world data from a large cohort of healthcare workers. Vaccine. 2022;40(4):650-655. doi:10.1016/j.vaccine.2021.12.014
Nguyen A, David JK, Maden SK, et al. Human leukocyte antigen susceptibility map for severe acute respiratory syndrome coronavirus 2. J Virol. 2020;94(13):e00510-e00520. doi:10.1128/JVI.00510-20
Pisanti S, Deelen J, Gallina AM, et al. Correlation of the two most frequent HLA haplotypes in the Italian population to the differential regional incidence of Covid-19. J Transl Med. 2020;18(1):352. doi:10.1186/s12967-020-02515-5
Degenhardt F, Ellinghaus D, Juzenas S, et al. Detailed stratified GWAS analysis for severe COVID-19 in four European populations. Hum Mol Genet. 2022;31(23):3945-3966. doi:10.1093/hmg/ddac158
Srivastava A, Hollenbach JA. The immunogenetics of COVID-19. Immunogenetics. 2023;75(3):309-320. doi:10.1007/s00251-022-01284-3
Augusto DG, Murdolo LD, Chatzileontiadou DSM, et al. A common allele of HLA is associated with asymptomatic SARS-CoV-2 infection. Nature. 2023;620(7972):128-136. doi:10.1038/s41586-023-06331-x
Bertinetto FE, Magistroni P, Mazzola GA, et al. The humoral and cellular response to mRNA SARS-CoV-2 vaccine is influenced by HLA polymorphisms. HLA. 2023;102(3):301-315. doi:10.1111/tan.15049
Magri C, Marchina E, Sansone E, et al. Genome-wide association studies of response and side effects to the BNT162b2 vaccine in Italian healthcare workers: increased antibody levels and side effects in carriers of the HLA-A*03:01 allele. HLA. 2023;102:707-719. doi:10.1111/tan.15157
Teijaro JR, Farber DL. COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol. 2021;21(4):195-197. doi:10.1038/s41577-021-00526-x
Crocchiolo R, Gallina AM, Pani A, et al. Polymorphism of the HLA system and weak antibody response to BNT162b2 mRNA vaccine. HLA. 2022;99(3):183-191. doi:10.1111/tan.14546
Bolze A, Neveux I, Schiabor Barrett KM, et al. HLA-A*03:01 is associated with increased risk of fever, chills, and stronger side effects from Pfizer-BioNTech COVID-19 vaccination. HGG Adv. 2022;3(2):100084. doi:10.1016/j.xhgg.2021.100084
Pani A, Cento V, Vismara C, et al. Results of the RENAISSANCE study: REsponse to BNT162b2 COVID-19 vacciNe-short- and long-term immune reSponSe evAluatioN in health care workErs. Mayo Clin Proc. 2021;96(12):2966-2979. doi:10.1016/j.mayocp.2021.08.013
Sacchi N, Castagnetta M, Miotti V, Garbarino L, Gallina A. High-resolution analysis of the HLA-A, -B, -C and -DRB1 alleles and national and regional haplotype frequencies based on 120 926 volunteers from the Italian bone marrow donor registry. HLA. 2019;94(3):285-295. doi:10.1111/tan.13613
Levin EG, Lustig Y, Cohen C, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med. 2021;385(24):e84. doi:10.1056/NEJMoa2114583
Goldberg Y, Mandel M, Bar-On YM, et al. Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med. 2021;385(24):e85. doi:10.1056/NEJMoa2114228
Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med. 2021;385(15):1393-1400. doi:10.1056/NEJMoa2114255
Mayer-Blackwell K, Ryu H, Codd AS, et al. mRNA vaccination boosts S-specific T cell memory and promotes expansion of CD45RA(int) T(EMRA)-like CD8(+) T cells in COVID-19 recovered individuals. Cell Rep Med. 2023;4(8):101149. doi:10.1016/j.xcrm.2023.101149
Buckley PR, Lee CH, Pereira Pinho M, et al. HLA-dependent variation in SARS-CoV-2 CD8 (+) T cell cross-reactivity with human coronaviruses. Immunology. 2022;166(1):78-103. doi:10.1111/imm.13451
Pontarotti P, Paganini J. COVID-19 pandemic: escape of pathogenic variants and MHC evolution. Int J Mol Sci. 2022;23(5):2665. doi:10.3390/ijms23052665
Mentzer AJ, O'Connor D, Bibi S, et al. Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection. Nat Med. 2023;29(1):147-157. doi:10.1038/s41591-022-02078-6
Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586(7830):594-599. doi:10.1038/s41586-020-2814-7
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi:10.1056/NEJMoa2034577
Hellerstein M. What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2? Vaccine X. 2020;11(6):100076. doi:10.1016/j.jvacx.2020.100076
Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489-1501.e15. doi:10.1016/j.cell.2020.05.015
Kurup D, Myers J, Schnell MJ. Current vaccine strategies against SARS-CoV-2: promises and challenges. J Allergy Clin Immunol. 2022;150(1):17-21. doi:10.1016/j.jaci.2022.05.008